Fundraising Fox

Umoja Biopharma, Inc.

Seattle, US Β· Founded 2019 Β· Delaware corporation Β· 248 employees on LinkedIn Β· 7 known investors

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.

BiotechHealthtech

Founders & leadership

Umoja Biopharma, Inc. was founded in 2019 by Andrew M. Scharenberg.

AM
Andrew M. ScharenbergFounderEntrepreneur Partner at MPM BioImpact
PS
Philip S. LowNamed on SEC filing

Board

IM
Irena MelnikovaBoard director
AF
Anna FrenchBoard director
RG
Robert GlassmanBoard director
JHJohn Hamer
John Hamerin𝕏Board directorManaging Partner, DCVC Bio at DCVC (Data Collective)
LELuke Evnin
Luke Evninin𝕏Board directorAdvisor at MPM BioImpact

Investors Β· 7

MPM BioImpactβœ“ verifiedBoston Β· $1M – $15M
DCVC Bioβœ“ verifiedPalo Alto
Qiming Venture Partners USAβœ“ verifiedCambridge
SoftBank Groupβœ“ verifiedTokyo
K2 HealthVenturesBoston Β· $10M – $100M
SoftBank Vision FundLondon
DCVC (Data Collective)reportedPalo Alto Β· $5M – $25M

Funding

SEC filings, press & company announcements

$210M disclosed across 1 of 2 rounds Β· 2021–2025

β–Ά$210MraisedJun 2021 Β· 29 investors Β· Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Philip S. LowDirector
  • Irena MelnikovaExecutive Officer
  • Anna FrenchDirector
  • Robert GlassmanDirector
  • John HamerDirector
  • Luke EvninDirector
  • Andrew M. ScharenbergExecutive Officer, Director
Offering amount
$210M
Amount sold
$210M
First sale
Jun 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR β†—

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors Β· 1

by search overlap
Bioworld37 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Umoja Biopharma, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestonesfinance.yahoo.com Β· Jan 2025Umoja Biopharma to Participate in Upcoming Investor Conferences in Septemberfinance.yahoo.com Β· Aug 2024

Frequently asked questions

What does Umoja Biopharma, Inc. do?
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.
Who founded Umoja Biopharma, Inc.?
Umoja Biopharma, Inc. was founded by Andrew M. Scharenberg in 2019.
Who are Umoja Biopharma, Inc.'s investors?
Umoja Biopharma, Inc.'s investors include MPM BioImpact, DCVC Bio, Qiming Venture Partners USA, SoftBank Group, K2 HealthVentures, SoftBank Vision Fund, DCVC (Data Collective).
How much funding has Umoja Biopharma, Inc. raised?
Umoja Biopharma, Inc. has disclosed $210M raised across 1 of its 2 known rounds.
Where is Umoja Biopharma, Inc. headquartered?
Umoja Biopharma, Inc. is headquartered in Seattle, US.